Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 18, 2023, titled "Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities".